Uswm CT

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Uswm CT sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting early-phase tilt upper quartile by trial count

Uswm CT: 7 sponsored US clinical trials, 2 recruiting.

Uswm CT sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neoplasms, with 3 trials.

Upper-quartile sponsor footprint

Uswm CT sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

SPEARHEAD-3 Pediatric Study

NCT05642455
RECRUITING Phase 1

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

NCT03391778
ACTIVE NOT RECRUITING Phase 2

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752
ACTIVE NOT RECRUITING Phase 2

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223
ACTIVE NOT RECRUITING Phase 2

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT06703346
ACTIVE NOT RECRUITING Phase 1

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859
ACTIVE NOT RECRUITING Phase 2

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04044768

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4

Therapeutic Areas

Neoplasms 3
Synovial Sarcoma 2
Ovarian Cancer 2
Non-small Cell Lung (NSCLC) 1
Esophagogastric Junction (EGJ) 1
Neuroblastoma (NBL) 1
Malignant Peripheral Nerve Sheath Tumor (MPNST) 1
Gastric (Stomach) Cancer 1
Myxoid Liposarcoma 1
Osteosarcoma 1

What is open in the Uswm CT pipeline

2 recruiting of 7 indexed (29% open).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Neoplasms (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Uswm CT: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Uswm CT sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Uswm CT3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Uswm CT sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Uswm CT sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Uswm CT page

7 registered trials is a research-attention snapshot, not an endorsement of Uswm CT or any single study.

  • 2 of Uswm CT's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Neoplasms is the condition Uswm CT studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neoplasms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Uswm CT pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.